These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 38286637)
1. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities. Latham BD; Geffert RM; Jackson KD Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637 [TBL] [Abstract][Full Text] [Related]
2. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Shah RR; Morganroth J; Shah DR Drug Saf; 2013 Jul; 36(7):491-503. PubMed ID: 23620168 [TBL] [Abstract][Full Text] [Related]
3. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Roskoski R Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477 [TBL] [Abstract][Full Text] [Related]
4. Integrating network pharmacology and drug side-effect data to explore mechanism of liver injury-induced by tyrosine kinase inhibitors. Tang M; Wu ZE; Li F Comput Biol Med; 2024 Mar; 170():108040. PubMed ID: 38308871 [TBL] [Abstract][Full Text] [Related]
5. FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced Solassol I; Pinguet F; Quantin X Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31671561 [TBL] [Abstract][Full Text] [Related]
6. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Wu P; Nielsen TE; Clausen MH Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956 [TBL] [Abstract][Full Text] [Related]
7. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. Deng J; Shao J; Markowitz JS; An G Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659 [TBL] [Abstract][Full Text] [Related]
8. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors. Du J; Yan H; Xu Z; Yang B; He Q; Wang X; Luo P Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1311-1325. PubMed ID: 34743659 [TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials. Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154 [TBL] [Abstract][Full Text] [Related]
10. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Roskoski R Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356 [TBL] [Abstract][Full Text] [Related]
11. Properties of FDA-approved small molecule protein kinase inhibitors. Roskoski R Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063 [TBL] [Abstract][Full Text] [Related]
12. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Teo YL; Ho HK; Chan A Br J Clin Pharmacol; 2015 Feb; 79(2):241-53. PubMed ID: 25125025 [TBL] [Abstract][Full Text] [Related]
13. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126 [TBL] [Abstract][Full Text] [Related]
14. Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis. Ayala-Aguilera CC; Valero T; Lorente-Macías Á; Baillache DJ; Croke S; Unciti-Broceta A J Med Chem; 2022 Jan; 65(2):1047-1131. PubMed ID: 34624192 [TBL] [Abstract][Full Text] [Related]
15. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. Abourehab MAS; Alqahtani AM; Youssif BGM; Gouda AM Molecules; 2021 Nov; 26(21):. PubMed ID: 34771085 [TBL] [Abstract][Full Text] [Related]
16. Recent advances in metabolism and toxicity of tyrosine kinase inhibitors. Zhao Q; Wu ZE; Li B; Li F Pharmacol Ther; 2022 Sep; 237():108256. PubMed ID: 35901905 [TBL] [Abstract][Full Text] [Related]
17. Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Roskoski R Pharmacol Res; 2022 Jan; 175():106037. PubMed ID: 34921994 [TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity of FDA-approved small molecule kinase inhibitors. Jiang H; Jin Y; Yan H; Xu Z; Yang B; He Q; Luo P Expert Opin Drug Saf; 2021 Mar; 20(3):335-348. PubMed ID: 33356646 [No Abstract] [Full Text] [Related]